Fig. 4From: Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)Five kinds of dual HDAC inhibitors in preclinical tests or early clinical trials. Dual HDAC inhibitors may offer more excellent therapeutic benefits in overcoming drug resistance and amplifying synergistic effects. However, the therapeutic potential of novel dual HDACis is urgently warranted further confirmation in clinical trialsBack to article page